Palvella Therapeutics (NASDAQ:PVLA) Price Target Raised to $97.00

Palvella Therapeutics (NASDAQ:PVLA) had its target price boosted by equities researchers at TD Cowen from $65.00 to $97.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. TD Cowen’s price objective would indicate a potential upside of 20.93% from the stock’s current price.

Other equities analysts also recently issued research reports about the company. Oppenheimer assumed coverage on Palvella Therapeutics in a research note on Tuesday, September 9th. They issued an “outperform” rating and a $85.00 target price on the stock. Chardan Capital upped their price target on shares of Palvella Therapeutics from $60.00 to $73.00 and gave the company a “buy” rating in a research report on Friday, September 26th. Raymond James Financial set a $54.00 price target on shares of Palvella Therapeutics and gave the stock an “outperform” rating in a research note on Tuesday, August 5th. Lifesci Capital assumed coverage on Palvella Therapeutics in a report on Monday, August 4th. They issued an “outperform” rating and a $90.00 price objective for the company. Finally, Truist Financial upped their price objective on Palvella Therapeutics from $56.00 to $80.00 and gave the stock a “buy” rating in a research note on Thursday, October 2nd. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Palvella Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $94.50.

Palvella Therapeutics Price Performance

Shares of PVLA traded up $4.46 during mid-day trading on Thursday, hitting $80.21. 109,717 shares of the company’s stock were exchanged, compared to its average volume of 115,740. Palvella Therapeutics has a 52 week low of $11.17 and a 52 week high of $83.00. The company has a 50-day simple moving average of $65.11 and a 200 day simple moving average of $42.13. The company has a market cap of $887.12 million, a PE ratio of -21.16 and a beta of -0.05.

Palvella Therapeutics (NASDAQ:PVLA) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.78) by ($0.08). On average, analysts anticipate that Palvella Therapeutics will post -3.69 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Alps Advisors Inc. acquired a new position in shares of Palvella Therapeutics during the 3rd quarter worth $344,000. AlphaQuest LLC bought a new position in shares of Palvella Therapeutics during the third quarter worth about $164,000. Archer Investment Corp bought a new stake in shares of Palvella Therapeutics in the 3rd quarter worth approximately $28,000. Federated Hermes Inc. bought a new position in shares of Palvella Therapeutics in the third quarter worth $21,255,000. Finally, Aspiriant LLC acquired a new position in shares of Palvella Therapeutics during the third quarter valued at approximately $367,000. Institutional investors and hedge funds own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc, formerly known as Pieris Pharmaceuticals Inc, is based in WAYNE, Pa.